Novo Nordisk on Monday revealed data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares ...

Novo Nordisk stock tumbled Monday after its experimental weight-loss drug failed to top its rival from Eli Lilly in a Phase 3 study.

Novo Nordisk's obesity drug CagriSema failed to outperform Eli Lilly's Mounjaro in the latest trial, causing a dip in Novo's ...

Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline ...

Novo Nordisk’s stock has dropped around 6.6% in premarket trading Monday following the release of its latest clinical trial data for CagriSema, a treatment for adults with obesity or overweight and ...

The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk‘s (NYSE:NVO) was ...

After Zepbound-maker Eli Lilly reduced the price of the weight-loss drug, competitor Novo Nordisk has cut the price of weight ...

Novo Nordisk said it will offer all doses of Wegovy for $499 a month to patients paying cash, a bid to reach consumers who ...

While the Super Bowl may not always be the ideal spot for pharma, cultural events like the Oscars can offer a more ...

Novo Nordisk is lowering the price of its weight-loss drug Wegovy to $499 per month for some patients paying out of pocket.

Novo Nordisk A/S (NVO) has slashed prices for its blockbuster weight-loss drug Wegovy as competition in the obesity drug market heats up, with Eli Lilly (LLY) as a key rival. The company launched ...

Novo Nordisk's trial results for CagriSema, a next-gen obesity and diabetes drug, showed a 15.7% weight reduction in overweight patients with type 2 diabetes. Despite promising outcomes, shares ...